GlassScriptPhysician profile
Stephen H Mascio
NPI 1790786853
$17,190.38
in general payments reported to CMS, 2019-2025
59 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,908 · 2020: $926 · 2021: $947 · 2022: $1,332 · 2023: $2,134 · 2024: $3,997 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,773 · Travel and Lodging: $982 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,772.70 |
| Travel and Lodging | $982.43 |
| Education | $322.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $4,513.49 | 2019-2025 | Xywav |
| Zoll Respicardia, INC. | $1,328.70 | 2023-2024 | Remede System |
| Novo Nordisk INC | $1,284.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,241.82 | 2019-2025 | Airsupra, Brilinta, Farxiga |
| Harmony Biosciences LLC | $1,024.51 | 2020-2025 | Wakix |
| Abbvie INC. | $948.17 | 2019-2025 | |
| Axsome Therapeutics, INC. | $759.68 | 2022-2025 | Sunosi, Auvelity |
| Avadel Cns Pharmaceuticals, LLC | $754.53 | 2023-2025 | Lumryz |
| Lilly USA, LLC | $744.49 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $529.02 | 2019-2025 | |
| Amgen INC. | $321.35 | 2019-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $300.73 | 2019-2025 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.81 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $205.87 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mascio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.